MA37432A1 - Virus modifié de la maladie de marek, et vaccins préparés à partir de celui-ci - Google Patents
Virus modifié de la maladie de marek, et vaccins préparés à partir de celui-ciInfo
- Publication number
- MA37432A1 MA37432A1 MA37432A MA37432A MA37432A1 MA 37432 A1 MA37432 A1 MA 37432A1 MA 37432 A MA37432 A MA 37432A MA 37432 A MA37432 A MA 37432A MA 37432 A1 MA37432 A1 MA 37432A1
- Authority
- MA
- Morocco
- Prior art keywords
- marke
- modified
- disease virus
- prepared therefrom
- viral agent
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 241000287828 Gallus gallus Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 235000013330 chicken meat Nutrition 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 208000006758 Marek Disease Diseases 0.000 abstract 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007918 pathogenicity Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/255—Marek's disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne un vaccin efficace contre la maladie de marek, qui est préparé en utilisant un virus de la maladie de marek (mdv) recombinant, souche cvi988, ayant été transformé avec une construction d'adn étranger qui comprend une longue séquence répétée terminale d'un virus de la réticuloendothéliose. Cet agent viral inoffensif élicite une réponse immunitaire très protectrice dans un poulet contre une exposition au mdv virulent sans entraîner de degré significatif de pathogénicité. Des formulations adaptées du vaccin destiné à être utilisé chez les poulets comprennent une dose immunisante efficace de ce nouvel agent viral, conjointement à un véhicule ou un diluant pharmaceutiquement acceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614142P | 2012-03-22 | 2012-03-22 | |
| PCT/US2013/032539 WO2013142377A2 (fr) | 2012-03-22 | 2013-03-15 | Virus modifié de la maladie de marek, et vaccins préparés à partir de celui-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA37432A1 true MA37432A1 (fr) | 2016-03-31 |
Family
ID=48045766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37432A MA37432A1 (fr) | 2012-03-22 | 2013-03-15 | Virus modifié de la maladie de marek, et vaccins préparés à partir de celui-ci |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20130251737A1 (fr) |
| EP (2) | EP3326646A1 (fr) |
| JP (1) | JP2015512396A (fr) |
| KR (5) | KR20230145532A (fr) |
| CN (1) | CN104602706A (fr) |
| AP (1) | AP2014007955A0 (fr) |
| AR (1) | AR090472A1 (fr) |
| BR (1) | BR112014023398A8 (fr) |
| CA (1) | CA2868099C (fr) |
| CR (1) | CR20140432A (fr) |
| DO (1) | DOP2014000215A (fr) |
| EA (1) | EA030866B1 (fr) |
| EC (1) | ECSP14023407A (fr) |
| ES (1) | ES2663610T3 (fr) |
| GE (1) | GEP201706650B (fr) |
| GT (1) | GT201400199A (fr) |
| HK (1) | HK1255682A1 (fr) |
| IL (1) | IL234721B (fr) |
| MA (1) | MA37432A1 (fr) |
| MX (1) | MX355332B (fr) |
| MY (1) | MY169061A (fr) |
| NL (1) | NL301087I2 (fr) |
| PE (1) | PE20150323A1 (fr) |
| PH (1) | PH12014502085B1 (fr) |
| TN (1) | TN2014000393A1 (fr) |
| UA (1) | UA117345C2 (fr) |
| WO (1) | WO2013142377A2 (fr) |
| ZA (1) | ZA201406884B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014023398A8 (pt) * | 2012-03-22 | 2022-08-16 | Merial Ltd | Vírus da doença de marek modidicado e vacinas feitas do mesmo |
| CN106397602B (zh) * | 2016-08-02 | 2019-06-18 | 青岛明勤生物科技有限公司 | 一种分子佐剂加强型鸡马立克氏病蛋白工程疫苗 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642574A (en) | 1970-04-29 | 1972-02-15 | Us Agriculture | Method for producing vaccine for immunization of poultry against marek{3 s disease |
| US4160024A (en) | 1978-05-01 | 1979-07-03 | Cornell Research Foundation, Inc. | Marek's disease vaccine |
| NL8401120A (nl) | 1984-04-09 | 1985-11-01 | Centraal Diergeneeskundig Inst | Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek. |
| US4895717A (en) | 1987-07-10 | 1990-01-23 | The United States Of America As Represented By The Secretary Of Agriculture | Revertant serotype 1 Marek's disease vaccine |
| US4895718A (en) | 1987-07-10 | 1990-01-23 | The United States Of America, As Represented By The Secretary Of Agriculture | Serotype 2 Marek's disease vaccine |
| CZ299473B6 (cs) | 1997-06-30 | 2008-08-06 | Rhone-Poulenc Rorer S. A. | Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva |
| US20050019348A1 (en) * | 2003-07-21 | 2005-01-27 | Reddy Sanjay M. | Marek's disease virus vaccine |
| BR112014023398A8 (pt) * | 2012-03-22 | 2022-08-16 | Merial Ltd | Vírus da doença de marek modidicado e vacinas feitas do mesmo |
| US9113301B1 (en) | 2014-06-13 | 2015-08-18 | Snapchat, Inc. | Geo-location based event gallery |
-
2013
- 2013-03-15 BR BR112014023398A patent/BR112014023398A8/pt not_active Application Discontinuation
- 2013-03-15 CA CA2868099A patent/CA2868099C/fr active Active
- 2013-03-15 MA MA37432A patent/MA37432A1/fr unknown
- 2013-03-15 EP EP17199985.7A patent/EP3326646A1/fr active Pending
- 2013-03-15 JP JP2015501821A patent/JP2015512396A/ja active Pending
- 2013-03-15 ES ES13714141.2T patent/ES2663610T3/es active Active
- 2013-03-15 KR KR1020237033927A patent/KR20230145532A/ko active Application Filing
- 2013-03-15 CN CN201380023461.4A patent/CN104602706A/zh active Pending
- 2013-03-15 EA EA201401044A patent/EA030866B1/ru unknown
- 2013-03-15 KR KR1020147029496A patent/KR20140146136A/ko not_active Application Discontinuation
- 2013-03-15 MX MX2014011388A patent/MX355332B/es active IP Right Grant
- 2013-03-15 KR KR1020237005968A patent/KR102586316B1/ko active IP Right Grant
- 2013-03-15 UA UAA201411478A patent/UA117345C2/uk unknown
- 2013-03-15 KR KR1020227000586A patent/KR102503316B1/ko active IP Right Grant
- 2013-03-15 WO PCT/US2013/032539 patent/WO2013142377A2/fr active Application Filing
- 2013-03-15 KR KR1020197024099A patent/KR20190100431A/ko not_active IP Right Cessation
- 2013-03-15 MY MYPI2014002694A patent/MY169061A/en unknown
- 2013-03-15 AP AP2014007955A patent/AP2014007955A0/xx unknown
- 2013-03-15 US US13/841,684 patent/US20130251737A1/en not_active Abandoned
- 2013-03-15 PE PE2014001444A patent/PE20150323A1/es not_active Application Discontinuation
- 2013-03-15 EP EP13714141.2A patent/EP2827898B1/fr active Active
- 2013-03-15 GE GEAP201313604A patent/GEP201706650B/en unknown
- 2013-03-22 AR ARP130100944A patent/AR090472A1/es not_active Application Discontinuation
-
2014
- 2014-09-18 IL IL234721A patent/IL234721B/en active IP Right Grant
- 2014-09-19 DO DO2014000215A patent/DOP2014000215A/es unknown
- 2014-09-19 GT GT201400199A patent/GT201400199A/es unknown
- 2014-09-19 CR CR20140432A patent/CR20140432A/es unknown
- 2014-09-19 ZA ZA2014/06884A patent/ZA201406884B/en unknown
- 2014-09-19 TN TNP2014000393A patent/TN2014000393A1/fr unknown
- 2014-09-22 PH PH12014502085A patent/PH12014502085B1/en unknown
- 2014-10-17 EC ECIEPI201423407A patent/ECSP14023407A/es unknown
-
2018
- 2018-11-20 HK HK18114829.8A patent/HK1255682A1/zh unknown
-
2019
- 2019-01-30 US US16/262,774 patent/US11510978B2/en active Active
-
2021
- 2021-01-12 NL NL301087C patent/NL301087I2/nl unknown
-
2022
- 2022-11-23 US US18/058,619 patent/US20230310589A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khan et al. | COVID-19 pandemic and vaccines update on challenges and resolutions | |
| Collins et al. | DNA vaccination for finfish aquaculture | |
| Rawat et al. | COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies | |
| Krammer | Novel universal influenza virus vaccine approaches | |
| Tipih et al. | Crimean–Congo hemorrhagic fever virus: advances in vaccine development | |
| Argilaguet et al. | BacMam immunization partially protects pigs against sublethal challenge with African swine fever virus | |
| Clegg et al. | Adjuvant solution for pandemic influenza vaccine production | |
| PH12018502684A1 (en) | A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate | |
| Chen et al. | Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement | |
| Spengler et al. | Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine | |
| Dong et al. | Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice | |
| Choi et al. | A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus | |
| Calvo-Pinilla et al. | Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge | |
| Guo et al. | A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates | |
| Uddbäck et al. | PB1 as a potential target for increasing the breadth of T-cell mediated immunity to Influenza A | |
| AU2003288510A8 (en) | Immunizing fish against viral infection | |
| MA37432A1 (fr) | Virus modifié de la maladie de marek, et vaccins préparés à partir de celui-ci | |
| Parks et al. | Human metapneumovirus reinfection in aged mice recapitulates increased disease severity in elderly humans infected with human metapneumovirus | |
| Aravind et al. | Protective effects of recombinant glycoprotein D based prime boost approach against duck enteritis virus in mice model | |
| WO2006062637A3 (fr) | Vaccination antigrippale | |
| Wan et al. | As a genetic adjuvant, CTA improves the immunogenicity of DNA vaccines in an ADP-ribosyltransferase activity-and IL-6-dependent manner | |
| Kim et al. | Stability and efficacy of the 3′-UTR A4G-G5A variant of viral hemorrhagic septicemia virus (VHSV) as a live attenuated immersion VHSV vaccine in olive flounder (Paralichthys olivaceus) | |
| Shollenberger et al. | Successful vaccination of immune suppressed recipients using Listeria vector HIV-1 vaccines in helminth infected mice | |
| Arnon et al. | Peptide-based synthetic recombinant vaccines with anti-viral efficacy | |
| Nag et al. | COVID-19 vaccines: an account of need and efficacy vs safety and challenges |